Open access

Elucidating the neuropathological and molecular heterogeneity of amyloid beta and tau in Alzheimer's disease through machine learning and transcriptomic integration

K. Zhao Hua Xie Tovia Jacobs Naomi L. Gaggi J. Fortea Nancy B. Carlisle G. Fonzo K. Pohl Ricardo S. Osorio Yu Zhang

Aug 2026 · Alzheimer's & Dementia · Vol 22 · 0 citations · 136 references

Medicine

Abstract

Functional brain network alterations associated with Alzheimer's disease (AD) pathology, including amyloid beta (Aβ) and phosphorylated tau (p‐tau), are difficult to interpret due to overlapping aging‐associated and non‐amyloid biological processes.

DOI PubMed Semantic Scholar

Read PDF

Similar papers

Open access Aug 2026

Plasma p‐tau217 detects Alzheimer's disease co‐pathology in cerebral amyloid angiopathy: Comparison to CSF biomarkers in the ANGMAR cohort

Plasma phosphorylated tau (p‐tau)217 is a robust biomarker of AD, but its performance in CAA remains unclear.

A. Fernández-Lebrero, J. Jiménez-Balado, G. García-Escobar et al. · Alzheimer's & Dementia · 0 citations

Open access Aug 2026

Brain morphometry patterns in the presence of Alzheimer's disease and/or LATE neuropathologic changes

Differences in brain morphometry patterns when one or both pathologies are present remain unclear, yet differences in brain morphometry patterns when one or both pathologies are present remain unclear.

Khalid Saifullah, A. Ridwan, Arnold M. Evia et al. · Alzheimer's & Dementia · 0 citations

Open access Aug 2026

Beyond amyloid: Contributions of neuroinflammation, cerebrovascular disease, and neurodegeneration to memory impairment in the oldest‐old, the LifeAfter90 Study

It is hypothesized that elevated neuroinflammation, indicated by reactive astrocytosis, acts on cerebrovascular disease and separately, on amyloid beta (Aβ) pathology, to promote downstream medial temporal lobe atrophy and memory impairment.

Batool M. Rizvi, P. Maillard, A. Posis et al. · Alzheimer's & Dementia · 0 citations

Open access Aug 2026

Regional astrocyte dysregulation and altered glymphatic‐related markers in Alzheimer's disease frontal cortex

Astrocyte dysfunction is central to Alzheimer's disease (AD), yet expression patterns of astrocytic markers remain poorly defined. We measured Aquaporin‐4 (AQP4) and glial fibrillary acidic protein (GFAP) in post‐mortem frontal cortex of AD patients and controls across BrainNet Europe (BNE) stages.

Harry Alexopoulos, X. Louka, E. D. de Natale et al. · Alzheimer's & Dementia · 0 citations

Open access Aug 2026

Amyloidogenic Amylin Signaling Links Diabetes to Dementia Pathogenesis

Selective targeting of circulating amyloidogenic amylin and its pathogenic signaling may enable biomarker development and disease-modifying therapies, and enable biomarker development and disease-modifying therapies.

F. Despa, T. Lashley · TIPS - Trends in Pharmacolog... · 0 citations

Open access Aug 2026

Unique transcriptomic alterations in 5XFAD;PS19 mouse model identify glial lipid dysregulation and coordinated microglial–oligodendrocyte responses

Alzheimer's disease (AD) features amyloid beta (Aβ) plaques and tau tangles, yet how their coexistence reshapes brain transcriptomic programs remains unclear.

Jung Hyun Park, Byungwook Kim, M. Al-Amin et al. · Alzheimer's & Dementia · 0 citations